Home > News Center
 
Contact Us
Shanghai BravoBio Co., Ltd.
Add: Suite 14E, Building #5, Haifu Garden, 1365 Dongfang Road, Lujiazui Financial and Trade Zone, Shanghai 200127, China
Tel: +86 21 2025 5516
Fax: +86 21 2025 5517
Email: bd@bravobio.com
News Center
 
Currently most promising therapeutic vaccines
Oct. 18, 2012
 
According to FierceVaccines, the top 10 promising therapeutic vaccines are: GVAX Pancreas (Pancreatic cancer), HyperAcute Pancreas (Pancreatic cancer), Rindopepimut (Brain cancer), VGX-3100 (Cervical cancer), PENNVAX-B (HIV infection), CAD106 (Alzheimer's disease), CV9201 (Non-small cell lung cancer), Prostvac (Castration-resistant prostate cancer), NeuVax (Breast cancer) and IMA901 (Renal cell carcinoma). The majority of the mentioned vaccines are targeting against cancer, which might influence the routine approaches of cancer treatment. Although many of these are in the early stage of R&D, hopefully they can open a new window for us to combat with diseases.
 
Italy bans Novartis influenza vaccines
Oct. 22, 2012
 
Italy banned the sales of Novartis flu vaccines due to the white particles found in the injections. Switzerland also recommended civilians not to use the vaccines until further notice. Novartis claimed their vaccines to be safe, yet they could not provide sufficient information on the white proteins and their potential effect.
 
Novartis and Wuxi AppTec to build new plants for biologics
Oct. 26, 2012
 
Manufacturing of biologics and biosimilars seems to be the industry trend. Novartis will invest $ 500M to build a new manufacturing facility in Singapore. It will be a manufacturing center for both biologics and pharmaceuticals. The construction will begin next year and finish by 2016.
WuXi AppTec has also opened a biologics manufacturing plant using all disposable technology in Wuxi, Jiangsu Province, to produce anti auto-immune drugs for the Chinese markets. WuXi AppTec claims that the plant to be first biologics plant in China to meet U.S. and EU standards.
 
India set down new rules for biologics
Oct. 30, 2012
 
India's Central Drug Standards Control Organization (CDSCO) released new guidance on good distribution practices (GDP) for biologics. It puts the safety burden on all the parties involved in the distribution of biologics from the site of manufacturer to the patients.
 
BravoBio attended Biologics World China 2012
Nov. 6, 2012
 
In early November, Biologics World China was held in Radisson Blu Hotel, Shanghai. Dr. Wu was invited to moderate a panel discussion on biotech start-ups' strategy.
 
Rotavirus vaccine was enlisted in immunization schedule in UK
Nov. 15, 2012
 
The 2-dose rotavirus vaccine from GSK, Rotarix, was added into the UK's childhood immunization program from September next year on for 3 years. Rotavirus is the most common cause of gastroenteritis in young children, and every child will have more than one rotavirus infection before the age of 5. Rotarix hit $266 million sales first half of 2012.
 
Current top-selling flu vaccines worldwide
Nov. 17, 2012
 
According to the estimation by EvaluatePharma, the total sales of flu vaccines will rise slightly in 2012. The best-selling flu vaccines are Fluzone/Vaxigrip from Sanofi/Sanofi Pasteur MSD, with $1.343 billion sales. The other 9 top-selling flu vaccines are: FluLaval/Fluviral (GSK; $375 million), Fluvirin (Novartis; $359 million), Influvac (Abbott; $188 million), FluMist (AstraZeneca; $162 million), BIKEN HA (Mitsubishi Tanabe; $108 million), OptaFlu (Novartis; $71 million), Inflexal V (Johnson & Johnson; $35 million), Anflu (Sinovac; $10 million) and Levrison (ROVI; $3 million).
 
FDA approved Novartis's flu vaccine produced from mammal cells
Nov. 21, 2012
 
FDA approved Novartis's novel flu vaccine Flucelvax, produced using cultured mammal cells instead of the traditional fertilized chicken eggs. Flucelvax is approved for use in adults 18 and older. The clinical study that involved 7700 people aged 18-49 in US and EU, indicated that Flucelvax was 83.8% effective compared with placebo.
 
WHO deemed Serum Institute's Meningitis Vaccine safe for warm storage
Nov. 26, 2012
 
The World Health Organization announced the meningitis vaccine MenAfriVac,safe for four days at up to 40 degrees. The vaccine is made by Serum Institute of India and costs only 50 cents per dose. By avoiding the expensive and inconvenient cold-chain shipment, this vaccine can better help people in Africa and other highly endemic areas.
Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next